Inhibrx Biosciences (INBX) EPS (Weighted Average and Diluted) (2023 - 2025)
Historic EPS (Weighted Average and Diluted) for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$2.28.
- Inhibrx Biosciences' EPS (Weighted Average and Diluted) rose 1971.83% to -$2.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.4, marking a year-over-year decrease of 11040.34%. This contributed to the annual value of $112.62 for FY2024, which is 64992.64% up from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' EPS (Weighted Average and Diluted) is -$2.28, which was up 1971.83% from -$1.85 recorded in Q2 2025.
- Inhibrx Biosciences' 5-year EPS (Weighted Average and Diluted) high stood at $125.48 for Q2 2024, and its period low was -$7.29 during Q4 2023.
- In the last 3 years, Inhibrx Biosciences' EPS (Weighted Average and Diluted) had a median value of -$3.02 in 2024 and averaged $9.08.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 301136.89% in 2024, then tumbled by 10147.43% in 2025.
- Inhibrx Biosciences' EPS (Weighted Average and Diluted) (Quarter) stood at -$7.29 in 2023, then surged by 56.18% to -$3.19 in 2024, then rose by 28.63% to -$2.28 in 2025.
- Its last three reported values are -$2.28 in Q3 2025, -$1.85 for Q2 2025, and -$2.8 during Q1 2025.